TNXP Tonix Pharmaceuticals Holding C

+0.03  (1%)
Previous Close 4.32
Open 4.35
Price To book 0.67
Market Cap 32.56M
Shares 7,486,000
Volume 82,700
Short Ratio 3.68
Av. Daily Volume 1,284,360

SEC filingsSee all SEC filings

  1. 8-K - Current report 17860978
  2. 8-K - Current report 17841010
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17839116
  4. DEF 14A - Other definitive proxy statements 17803148
  5. 8-K - Current report 17801171

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Initiation of first of two Phase 3 trials announced March 28, 2017 in military-related PTSD 1Q 2017. Interim analysis due 1H 2018 with top-line data due 2H 2018.
TNX-102 SL
Post-traumatic stress disorder (PTSD)
Phase 2 data released February 2016 did not meet primary endpoint
Episodic tension-type headache
Phase 3 data released September 6, 2016. Primary endpoint not met. Program discontinued
TNX-102 SL

Latest News

  1. Tonix Pharmaceuticals to Present Additional Clinical Results of Military-Related PTSD Study at the 2017 American Society of Clinical Psychopharmacology Annual Meeting
  2. Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD
  3. Today's Research Reports on Stocks to Watch: Tonix Pharmaceuticals and Calithera Biosciences
  4. TNXP: Interim Analysis for HONOR Study Expected in 1H18
  5. Tonix reports 1Q loss
  6. Tonix Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Programs Update
  7. Tonix Pharmaceuticals to Present PTSD Clinical Data at the Society of Biological Psychiatry 72nd Annual Scientific Convention
  8. Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-102 SL Composition and Formulation: Designed for Transmucosal Absorption and Bedtime Daily Use
  9. TNXP: Potential for Only One Phase 3 Trial Needed for TNX-102 SL in PTSD
  10. Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Programs Update
  11. Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
  12. Windtree Therapeutics and Tonix Pharmaceuticals on the Rise after FDA Clinical Trial News
  13. Tonix Pharmaceuticals Reports Results from U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting on TNX-102 SL for Posttraumatic Stress Disorder
  14. Tonix Pharmaceuticals Completes $8 Million Public Offering of Common Stock
  15. Tonix Pipeline Review Closer to the Commercialization of a New PTSD Treatment
  16. Is This The Start of a Turnaround for DryShips and Tonix, or will Management Burn Investors Again
  17. Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
  18. Tonix Pharmaceuticals and Athersys Advance as FDA Clinical Trials Move Forward
  19. Tonix Pharmaceuticals Prices Public Offering of 1,800,000 Shares of Common Stock